- Home
- EMX vs FDMT Comparison
EMX vs FDMT Comparison
Compare EMX & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EMX
- FDMT
- Stock Information
- Founded
- EMX N/A
- FDMT 2013
- Country
- EMX Canada
- FDMT United States
- Employees
- EMX N/A
- FDMT N/A
- Industry
- EMX
- FDMT Biotechnology: Pharmaceutical Preparations
- Sector
- EMX
- FDMT Health Care
- Exchange
- EMX Nasdaq
- FDMT Nasdaq
- Market Cap
- EMX 461.8M
- FDMT 391.8M
- IPO Year
- EMX N/A
- FDMT 2020
- Fundamental
- Price
- EMX $5.22
- FDMT $9.61
- Analyst Decision
- EMX Strong Buy
- FDMT Strong Buy
- Analyst Count
- EMX 2
- FDMT 8
- Target Price
- EMX $5.38
- FDMT $30.63
- AVG Volume (30 Days)
- EMX 1.0M
- FDMT 688.5K
- Earning Date
- EMX 11-06-2025
- FDMT 11-12-2025
- Dividend Yield
- EMX N/A
- FDMT N/A
- EPS Growth
- EMX N/A
- FDMT N/A
- EPS
- EMX 0.04
- FDMT N/A
- Revenue
- EMX $29,864,000.00
- FDMT $33,000.00
- Revenue This Year
- EMX $11.08
- FDMT $9,656.76
- Revenue Next Year
- EMX $3.72
- FDMT N/A
- P/E Ratio
- EMX $115.34
- FDMT N/A
- Revenue Growth
- EMX N/A
- FDMT N/A
- 52 Week Low
- EMX $1.65
- FDMT $2.24
- 52 Week High
- EMX $5.39
- FDMT $9.84
- Technical
- Relative Strength Index (RSI)
- EMX 69.60
- FDMT 63.90
- Support Level
- EMX $4.82
- FDMT $8.11
- Resistance Level
- EMX $5.39
- FDMT $9.03
- Average True Range (ATR)
- EMX 0.22
- FDMT 0.52
- MACD
- EMX 0.02
- FDMT -0.01
- Stochastic Oscillator
- EMX 85.47
- FDMT 76.79
About EMX EMX Royalty Corporation (Canada)
EMX Royalty Corp and its subsidiaries operate as a royalty and prospect generator engaged in exploring for and generating royalties from, metals and minerals properties. The company is a precious, and base metals royalty company. The Company augments royalty generation with royalty acquisitions and strategic investments. EMX's royalty and mineral property portfolio consists of properties in North America, Europe, Turkiye, Latin America, Morocco and Australia.
About FDMT 4D Molecular Therapeutics Inc.
4D Molecular Therapeutics Inc is a clinical-stage gene therapy company engaged in the development of product candidates using targeted and evolved AAV vectors. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-125, 4D-110, and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector) 4D-310.